^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT142

    i
    Other names: BNT142
    Associations

    News

    Trials
    Company:
    BioNTech
    Drug class:
    CD3 agonist, CLDN6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=288, Recruiting, BioNTech SE
    Trial completion date • Trial primary completion date • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    BNT142
    1year
    A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors. (ASCO 2023)
    Additional sites will be opened in Europe, USA, and Asia in 2023. Clinical trial information: NCT05262530.
    P1/2 data • Clinical
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    BNT142
    over1year
    Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=288, Recruiting, BioNTech SE | N=216 --> 288
    Enrollment change
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    BNT142
    2years
    Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6 Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    BNT142
    2years
    Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6 Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Not yet recruiting, BioNTech SE
    New P1/2 trial
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    BNT142